Skip to main content

Gilead Announces Positive Remdesivir Data in U.S. Coronavirus Treatment Study

Publish date:
Video Duration:

We have some breaking news from Gilead. 

The drugmaker was briefly halted in premarket trading and then released that remdesivir--its experimental drug--met a government study primary endpoint.

Remdesivir is being tested in multiple clinical trials and it is being used to treat severely ill COVID-19 patients who have been hospitalized. 

The study is being conducted by the National Institute of Allergy and Infectious Diseases. 

Remdesivir has been getting a slew of headlines--both good and bad--in the past couple of weeks. 

Stat news reported positive findings based on a leaked video from a trial in Chicago on April 16 and then the World Health Organization accidentally posted a study on remdesivir from China, which reportedly showed that the drug wasn't helping to speed up the recovery of patients with COVID-19. Gilead had said, however, that the data noted a "potential benefit."

"These study results complement data from the placebo-controlled study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases and help to determine the optimal duration of treatment with remdesivr," noted Merdad Parsey, Chief Medical Officer at Gilead. 

The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Parsey said.

Watch More of the Latest Videos from TheStreet and Jim Cramer

Related Videos